Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation

被引：1

作者：

Canichella, Martina ^{[1
]}

de Fabritiis, Paolo ^{[1
,2
]}

机构：

[1] St Eugenio Hosp, ASL Roma2, Haematol Unit, Rome, Italy

[2] Tor Vergata Univ, Dept Biomed & Prevent, I-00133 Rome, Italy

来源：

BIOMEDICINES | 2024年 / 12卷 / 08期

关键词：

acute myeloid leukemia (AML); allogeneic stem cell transplantation (ASCT); cellular therapy; donor lymphocyte infusion (DLI); chimeric antigen receptor (CAR)-T cells; next-generation CAR-T cells; universal CAR-T (UCAR-T); UniCAR technology; CHIMERIC ANTIGEN RECEPTOR; DONOR LYMPHOCYTE INFUSION; CAR-T-CELLS; INDUCED KILLER-CELLS; LEUKOCYTE INFUSIONS; RISK-FACTORS; AML PATIENTS; IMMUNOTHERAPY; THERAPY; ADULTS;

D O I：

10.3390/biomedicines12081721

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Allogeneic stem cell transplant (ASCT) remains the only treatment option for patients with high-risk acute myeloid leukemia (AML). Recurrence of leukemic cells after ASCT represents a dramatic event associated with a dismal outcome, with a 2-year survival rate of around 20%. Adoptive cell therapy (ACT) is a form of cell-based strategy that has emerged as an effective therapy to treat and prevent post-ASCT recurrence. Lymphocytes are the principal cells used in this therapy and can be derived from a hematopoietic stem cell donor, the patient themselves, or healthy donors, after being engineered to express the chimeric antigen receptor (CAR-T and UniCAR-T). In this review, we discuss recent advances in the established strategy of donor lymphocyte infusion (DLI) and the progress and challenges of CAR-T cells.

引用

页数：16

共 84 条

[1] Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia [J].

Albinger, Nawid ;

Pfeifer, Rita ;

Nitsche, Marcus ;

Mertlitz, Sarah ;

Campe, Julia ;

Stein, Katja ;

Kreyenberg, Hermann ;

Schubert, Ralf ;

Quadflieg, Melissa ;

Schneider, Dina ;

Kuehn, Michael W. M. ;

Penack, Olaf ;

Zhang, Congcong ;

Moeker, Nina ;

Ullrich, Evelyn .

BLOOD CANCER JOURNAL, 2022, 12 (04)

[2] Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia [J].

Anguille, S. ;

Van Tendeloo, V. F. ;

Berneman, Z. N. .

LEUKEMIA, 2012, 26 (10) :2186-2196

[3] The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells [J].

Bachmann, Michael .

IMMUNOLOGY LETTERS, 2019, 211 :13-22

[4] TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer [J].

Berdien, B. ;

Mock, U. ;

Atanackovic, D. ;

Fehse, B. .

GENE THERAPY, 2014, 21 (06) :539-548

[5] Efficacy of Azacitidine and Prophylactic Donor Lymphocyte Infusion after HSCT in Pediatric Patients with Acute Myelogenous Leukemia: A Retrospective Pre-Post Study [J].

Booth, Natalie ;

Mirea, Lucia ;

Huschart, Emily ;

Miller, Holly ;

Salzberg, Dana ;

Campbell, Courtney ;

Beebe, Kristen ;

Schwalbach, Charlotte ;

Adams, Roberta H. ;

Ngwube, Alexander .

TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (05) :330e1-330e7

[6] Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells [J].

Cauchois, Raphael ;

Castagna, Luca ;

Pagliardini, Thomas ;

Harbi, Samia ;

Calmels, Boris ;

Bramanti, Stefania ;

Granata, Angela ;

Lemarie, Claude ;

Maisano, Valerio ;

Legrand, Faezeh ;

Fuerst, Sabine ;

Faucher, Catherine ;

Weiller, Pierre-Jean ;

Chabannon, Christian ;

Blaise, Didier ;

Devillier, Raynier .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) :570-573

[7] Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility [J].

Celichowski, Piotr ;

Turi, Marcello ;

Charvatova, Sandra ;

Radhakrishnan, Dhwani ;

Feizi, Neda ;

Chyra, Zuzana ;

Simicek, Michal ;

Jelinek, Tomas ;

Bago, Juli Rodriguez ;

Hajek, Roman ;

Hrdinka, Matous .

JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)

[8] CAR T cells: driving the road from the laboratory to the clinic [J].

Cheadle, Eleanor J. ;

Gornall, Hannah ;

Baldan, Vania ;

Hanson, Vivien ;

Hawkins, Robert E. ;

Gilham, David E. .

IMMUNOLOGICAL REVIEWS, 2014, 257 (01) :91-106

[9] Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia [J].

Chen, L. ;

Mao, H. ;

Zhang, J. ;

Chu, J. ;

Devine, S. ;

Caligiuri, M. A. ;

Yu, J. .

LEUKEMIA, 2017, 31 (08) :1830-1834

[10] Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change [J].

Christopeit, Maximilian ;

Kuss, Oliver ;

Finke, Juergen ;

Bacher, Ulrike ;

Beelen, Dietrich Wilhelm ;

Bornhaeuser, Martin ;

Schwerdtfeger, Rainer ;

Bethge, Wolfgang Andreas ;

Basara, Nadezda ;

Gramatzki, Martin ;

Tischer, Johanna ;

Kolb, Hans-Jochem ;

Uharek, Lutz ;

Meyer, Ralf G. ;

Bunjes, Donald ;

Scheid, Christof ;

Martin, Hans ;

Niederwieser, Dietger ;

Kroeger, Nicolaus ;

Bertz, Hartmut ;

Schrezenmeier, Hubert ;

Schmid, Christoph .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3259-+

← 1 2 3 4 5 6 7 8 9 →